Psychiatric changes after stereotactic laser amygdalohippocampotomy for medial temporal lobe epilepsy
Epilepsy & Behavior · 2023-08 · 145 · 109332
DOI: 10.1016/j.yebeh.2023.109332 ↗Kurz gefasst
Fachartikel in der Zeitschrift Epilepsy & Behavior, 2023-08. Verfasst von Karanbir Padda und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, New York-Presbyterian/Weill Cornell Medical Center, New York, NY, USA. Hauptthemen laut MEDLINE: Epilepsy, Temporal Lobe, Psychosurgery. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIMH NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
PURPOSE: Stereotactic laser amygdalohippocampotomy (SLAH) is a minimally invasive surgical treatment for drug-resistant temporal lobe epilepsy (TLE) that has comparable rates of seizure freedom to traditional open resective TLE surgery. The objective of this study was to determine psychiatric outcome (i.e., depression and anxiety changes, psychosis) after SLAH, to explore possible contributory factors to these changes, and to determine the prevalence of de novo psychopathology. METHODS: We explored mood and anxiety in 37 adult patients with TLE undergoing SLAH using the Beck psychiatric symptoms scales (i.e., Beck Depression Inventory-II [BDI-II] and Beck Anxiety Inventory [BAI]) preoperatively and 6 months following surgery. Multivariable regression analysis was conducted to identify predictors of worse depression or anxiety symptoms following SLAH. The prevalence of de novo psychopathology following SLAH was also determined. RESULTS: We found a significant decrease in BDI-II (mean decline from 16.3 to 10.9, p = 0.004) and BAI (mean decline from 13.3 to 9.0, p = 0.045) scores following SLAH at the group level. While the rate of resolution of depression (from 62% to 49%) did not achieve statistical significance (p = 0.13, McNemar's), the rate of resolution of anxiety (from 57% to 35%) was statistically significant (p = 0.03, McNemar's). The de novo rate of psychopathology (i.e., new onset depression or anxiety) following SLAH was 1 of 7 (14%). Using a metric of meaningful change rather than complete symptom resolution, 16 of 37 (43%) patients experienced improvement in depression and 6 of 37 (16%) experienced worsening. For anxiety, 14 of 37 (38%) experienced meaningful improvement and 8 of 37 (22%) experienced worsening. Baseline performance on the Beck Scales was the only factor contributing to outcome status. DISCUSSION: In one of the first studies to evaluate psychiatric outcomes after SLAH, we found promising overall trends toward stability or significant improvement in symptom burden at the group level for both depression and anxiety. There was also a significant improvement in clinical anxiety, though the decrease in clinical depression was not significant, likely owing to the limitations of sample size. SLAH may improve overall psychiatric symptoms, similarly to traditional resective TLE surgery, but de novo psychopathology and postoperative psychiatric morbidity remain significant issues, and larger samples are necessary to determine causal contributory factors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry, New York-Presbyterian/Weill Cornell Medical Center, New York, NY, USA.
- Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA.
- Department of Physical Medicine & Rehabilitation, Wayne State University School of Medicine, Detroit, MI, USA.
- Department of Neurosurgery, Washington University School of Medicine, St. Louis, MO, USA.
- Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA; Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA; Coulter Department of Biomedical Engineering, Emory Univ…
- Department of Neurology, Emory University School of Medicine, Atlanta, GA, USA; Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA; Department of Neurology, University of Washington School o…
Förderung
- NIA NIH HHS
- NIMH NIH HHS
- NCATS NIH HHS
- NINDS NIH HHS
- NIBIB NIH HHS
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Padda, K., Matthews, R. E., Karakis, I., Hewitt, K. C., Valentin, E., Block, C., Shade, T., Dickey, A., Millis, S., Willie, J. T., Gross, R. E., & Drane, D. L. (2023). Psychiatric changes after stereotactic laser amygdalohippocampotomy for medial temporal lobe epilepsy. Epilepsy & Behavior, 145, 109332. https://doi.org/10.1016/j.yebeh.2023.109332
Vancouver
Padda K, Matthews RE, Karakis I, Hewitt KC, Valentin E, Block C, et al. Psychiatric changes after stereotactic laser amygdalohippocampotomy for medial temporal lobe epilepsy. Epilepsy & Behavior. 2023;145:109332. doi:10.1016/j.yebeh.2023.109332
BibTeX
@article{Padda2023,
author = {Padda, Karanbir and Matthews, Rebecca E and Karakis, Ioannis and Hewitt, Kelsey C and Valentin, Edward and Block, Cady and Shade, Taylor and Dickey, Adam and Millis, Scott and Willie, Jon T and Gross, Robert E and Drane, Daniel L},
title = {Psychiatric changes after stereotactic laser amygdalohippocampotomy for medial temporal lobe epilepsy},
journal = {Epilepsy & Behavior},
year = {2023},
volume = {145},
pages = {109332},
doi = {10.1016/j.yebeh.2023.109332}
}
EUVIMED